---
title: "Varegacestat (AL102) in Desmoid tumors: Long-term morbidity"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Long-term morbidity. Topics: Morbidity from local infiltration and recurrence, Functional deficits and disfigurement after surgery, Amputation, Long-term use of analgesics and other medications, and 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Morbidity from local infiltration and recurrence

> “The lesions do not have the ability to metastasize, but progressive disease and local recurrence can lead to significant morbidity.”

Source: [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/)

> “The morbidity and mortality associated with DT largely depend on the tumor location, as this determines the adjacent structures that the DT will infiltrate or compress.”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.7-2"></a>

### Functional deficits and disfigurement after surgery

> “Although surgery is a potential treatment option, complete excision with negative margins is not often possible, the postsurgery recurrence rate is high, and surgery can result in disfigurement and/or loss of function.”
> “Tumors in the extremities have the highest risk of recurrence (30%-90%).”
> “Although effective in specific cases, surgery may be associated with poor long-term functional outcomes and higher economic costs.”

Source: [Fernandez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37099290/)

<a id="topic-2.2.1.7-3"></a>

### Amputation

> “Amputation was reported for 7% (12/163) of participants who underwent surgery, with most (83%, 10/12) experiencing tumor regrowth or recurrence post-amputation.”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.7-4"></a>

### Long-term use of analgesics and other medications

> “A total of 56% of DT patients used chemotherapeutic agents, tyrosine kinase inhibitors, NSAIDs, opioids, antidepressants, or steroids at some point during the three years before their DT diagnoses. In contrast, 70% of surgically treated and 63% of non-surgically treated patients used one of these drugs in the subsequent three years, including NSAIDs (45% surgical vs. 33% non-surgical), opioids (39% surgical vs. 27% non-surgical), and steroids (22% surgical vs. 18% non-surgical).”

Source: [Anneberg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35121405/)

| Medication for desmoid tumor symptom management | Overall (N = 322), n (%) | Current presence of a desmoid tumor (n = 225), n (%) | No current desmoid tumor (n = 97), n (%) |
| --- | --- | --- | --- |
| NSAIDs | “151 (47)” | “103 (46)” | “48 (49)” |
| Opioids | “61 (19)” | “45 (20)” | “16 (16)” |
| Antidepressants | “60 (19)” | “41 (18)” | “19 (20)” |
| Anticonvulsants | “36 (11)” | “26 (12)” | “10 (10)” |

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.7-5"></a>

### Chronic pain and dependency on analgesics

> “Pain can further debilitate patients with DT and lead to functional limitations, while the management of pain with narcotics can lead to potential dependency on painkillers”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

> “Severe pain/narcotic dependency, tumor size larger than 10 cm, and need for total parenteral nutrition were shown to further define survival within stages.”

Source: [Quintini et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22323009/)

<a id="topic-2.2.1.7-6"></a>

### Persistent symptoms with current disease

> “Participants with the presence of DT at survey completion reported significantly worse scores for pain, extra-abdominal symptoms, fatigue, physical functioning, and sleep in comparison to those without the current presence of a DT ( P < 0.05).”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.7-7"></a>

### Intestinal failure and home parenteral nutrition in familial adenomatous polyposis-associated intra-abdominal desmoids

> “Intra-abdominal desmoid tumors (IADTs) are a common complication of familial adenomatous polyposis (FAP).”
> “Medical and surgical treatments may be ineffective in preventing complications, which can cause intestinal failure.”
> “One hundred fifty-four patients were included and divided into 2 groups: HPN (n = 41, 26.6%) and non-HPN (n = 113, 73.4%).”
> “HPN, although a life-saving treatment, is an independent poor prognostic factor associated with high morbidity and mortality.”

Source: [Shatnawei et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23319384/)

<a id="topic-2.2.1.7-8"></a>

### Constraints on colorectal surgery in familial adenomatous polyposis

> “In a substantial proportion of patients with an ileorectal anastomosis, it was impossible to convert the ileorectal anastomosis to an ileal pouch-anal anastomosis as a result of desmoid development.”

Source: [Nieuwenhuis et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18237870/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
